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http://dx.doi.org/10.1016/j.stemcr.2016.05.015SUMMARYUnderstanding the molecular mechanisms that regulate b cell mass and proliferation is important for the treatment of diabetes.
Here, we identified domperidone (DPD), a dopamine D2 receptor (DRD2) antagonist that enhances b cell mass. Over time, islet
b cell loss occurs in dissociation cultures, and this was inhibited by DPD. DPD increased proliferation and decreased apoptosis of
b cells through increasing intracellular cAMP. DPD prevented b cell dedifferentiation, which together highly contributed to the
increased b cell mass. DRD2 knockdown phenocopied the effects of domperidone and increased the number of b cells. Drd2 over-
expression sensitized the dopamine responsiveness of b cells and increased apoptosis. Further analysis revealed that the adenosine
agonist 50-N-ethylcarboxamidoadenosine, a previously identified promoter of b cell proliferation, acted with DPD to increase the
number of b cells. In humans, dopamine also modulates b cell mass through DRD2 and exerts an inhibitory effect on adenosine
signaling.INTRODUCTION
Diabetes is a progressive disorder characterized by elevated
blood glucose levels, which causes organ complications.
Both type 1 and late-stage type 2 diabetes lead to depletion
of pancreatic islet b cells. Islet transplantation is a prom-
ising therapy to improve glycemic control. However, organ
shortages and the loss of islet cells shortly after transplanta-
tion are major obstacles. Advances have been made in the
generation of mature pancreatic b cells from pluripotent
stem cells to overcome these problems. However, a thor-
ough understanding of b cell mass regulation is required.
b Cells have been reported to have the potential to pro-
liferate after experimental ablation, such as chemical
treatment or partial pancreatectomy (Bonner-Weir et al.,
2010) (Cano et al., 2008; Nir et al., 2007; Xu et al., 2008).
Although controversial, b cells have also been reported to
be generated from other cell sources, such as pancreatic
ducts (Finegood et al., 1999; Sharma et al., 1999; Xu
et al., 2008) and endogenous progenitor or trans-differenti-
ated a, d, or acinar cells, under specific conditions that lead
to a nearly complete loss of b cells (Baeyens et al., 2005;
Collombat et al., 2009; De Breuck et al., 2003, 2006; Xu
et al., 2008). During regeneration, simple self-replication
of b cells has been shown to be the primary source of
new b cells (Dor et al., 2004; Kataoka et al., 2013). However,
the mechanisms that regulate b cell proliferation are not
well understood. Glucose has been identified as a signal
that controls b cell proliferation through glucokinase acti-Stem
This is an open access article under the Cvation and subsequent downregulation of cyclin D2
expression (Porat et al., 2011; Salpeter et al., 2011). In addi-
tion, severalmolecules, such as adenosine kinase inhibitors
and glucagon-like peptide-1 (GLP-1), have been shown to
promote b cell proliferation (Andersson et al., 2012; Ber-
nal-Mizrachi et al., 2014). Moreover, dedifferentiation has
also been shown to be a mechanism that triggers b cell
loss (Talchai et al., 2012). Many studies have been aimed
at identifying molecules that enhance b cell proliferation,
which could restore proper b cell function and ultimately
cure type 1 and type 2 diabetes. Recently, in a screening
of a pharmacologically bioactive small-molecular com-
pound library, we identified molecules that enhance the
differentiation of mouse embryonic stem cells (ESCs) into
pancreatic b cells. We extended our study and established
a primary islet culture system for screening small chemical
compounds that enhance b cell proliferation. Here, we
identified domperidone (DPD), a dopamine D2 recep-
tor (DRD2) antagonist, as a potent enhancer of b cell
proliferation and investigated the underlying molecular
mechanism.RESULTS
A Screening System for Chemicals that Promote b Cell
Proliferation
To screen for chemicals that promote b cell proliferation,
we established an islet dissociation culture system, inCell Reports j Vol. 7 j 95–109 j July 12, 2016 j ª 2016 The Author(s). 95
C BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
Figure 1. A Screening System for Chemi-
cals that Promote b Cell Proliferation
A high-throughput screening system was
established to identify chemicals that pro-
mote b cell proliferation.
(A) Schematic drawing of the screening
system. Dissociated islet cells were plated in
a gelatin-coated 384-well plate at 2,000
cells/plate and cultured for 5 days, treated
with EdU or test chemicals on days 3–5, and
assayed on day 5.
(B–E) Immunocytochemistry analysis of the
islet culture on day 1 (B, C, D) or day 5 (E).
(F) Total number of cells per well, showing
the number of endocrine cells (PP+, Sst+,
Gcg+, Ins+), exocrine cells (Amy+), and
mesenchymal cells (Vim+) in the culture on
day 1 (d1), d3, and d5 (mean ± SD, three
independent experiments, each with four
replicates).which islets were dissociated into single cells and plated
onto gelatin-coated 384-well plates.
In our islet dissociation culture, endocrine cell types were
obtained at a proportion that reflected normal islet compo-
sition, i.e., approximately 80% insulin-positive (Ins+) cells,
20% glucagon (Gcg)+ cells, 5% somatostatin (Sst)+ cells,
and 1% pancreatic polypeptide (PP)+ cells (Figures 1B–1F,
day 1). Other cell types, such as vimentin (Vim)+ mesen-
chyme cells, amylase (Amy)+ exocrine cells, and others,
were also observed (Figure 1F). In the culture, the cells ap-
peared to gradually become apoptotic, and the number of
islet cells decreased with time.
To determine the assay conditions, we first tested the
period of 5-ethynyl-20-deoxyuridine (EdU) exposure of
the dissociated islets. EdU incorporation in Ins+ cells
increased for up to 72 hr of exposure to EdU (Figure S1A).
EdU incorporation in Ins+ cells was observed at a substan-
tial level on days 1–3 or days 3–5, and significantly
decreased on days 5–7 after islet dissociation (Figure S1B).
Therefore in our initial screen, the 48-hr EdU exposure
was adopted and chemicals were added to the cultures
beginning on days 3–5, and the numbers of total cells96 Stem Cell Reports j Vol. 7 j 95–109 j July 12, 2016and Ins+ cells were counted and EdU positivity in Ins+ cells
determined on day 5.
Domperidone, a DRD2 Antagonist, Promotes b Cell
Proliferation
We tested a library of 1,120 biologically active compounds
arrayed as single compounds in DMSO. Candidate com-
pounds that increased the numbers of total cells and
Ins+ cells were selected as primary hits. Of our hit com-
pounds, a DRD2 antagonist, DPD, showed the strongest
effect.
DPD is known to be a specific antagonist of DRD2, which
is a G-protein-coupled receptor (GPCR). DRD2 is known to
mediate Gai signaling, which inhibits adenylate cyclase
and decreases cyclic AMP (cAMP) upon dopamine binding.
Addition of DPD increased the number of EdU+ prolifera-
tive Ins+ b cells (Figures 2A–2B0) in the culture on day 5.
DPD specifically increased the proportion of EdU+ cells
among the Ins+ cells (Figure 2C), resulting in a specific in-
crease in Ins+ cells but not other cell types (Figure 2D).
Time-dependent application of DPD revealed that early
application of DPD from day 1 or day 3 increased b cell
Figure 2. Domperidone Enhances b Cell
Proliferation by Antagonizing the Dopa-
mine Apoptotic Signal in Islets
Treatment with dopamine increased EdU
incorporation and decreased cell event
positivity in b cells, analyzed by immuno-
cytochemistry.
(A–B0) Representative images are shown.
EdU incorporation increased in insulin-
positive (Ins+) cells treated with domper-
idone (DPD).
(C) The proportion of EdU-positive prolif-
erating cells within the Ins+ cell population
increased following DPD treatment (12 in-
dependent experiments, each with three
to four replicates).
(D) Total cell numbers per well, showing the
number of endocrine cells (PP+, Sst+, Gcg+,
Ins+), exocrine cells (Amy+), and mesen-
chymal cells (Vim+) in the culture on day 5
without (Cont) or with DPD. The data shown
in Cont are identical to those in Figure 1F d5
(three independent experiments, each with
four replicates).
(E–F0) The Ins+ cells in the islet cells become
cell event-positive apoptotic cells on day 5.
The appearance of apoptosis was inhibited
by DPD treatment on days 3–5.
(G) Percentage of apoptotic cells among the
Ins+ cells on day 5 (six independent exper-
iments, each with three to four replicates).
(H) The number of Ins+ cells per well after
4 days of chemical treatment (days 3–7)
(four independent experiments, each with
three to four replicates). Data represent
mean ± SD. **p < 0.01 compared with
control (open bars); NS, not significant. DA,
dopamine. Scale bar, 50 mm.number effectively, but late application (on day 5) pro-
duced minimal effects (Figure S2).
Over time, the islet cells in our culture assays formed
clusters, stopped proliferating, and became caspase-3/7-
positive (cell event-positive) apoptotic cells, which led to
a decrease in cell number. We then assessed whether
DPD could prevent b cell apoptosis. As expected, in the
presence of DPD, apoptosis was significantly reduced (Fig-
ures 2E–2G). Taken together, our results showed that DPD
increased cell proliferation and decreased apoptosis of
Ins+ cells by antagonizing the action of dopamine
through DRD2.
To determine whether dopamine acts as an upstream
signaling molecule that modulates b cell proliferation and
cell death, we tested the effects of dopamine and cAMP
on proliferation and apoptosis. The results showed that
dopamine decreased the number of Ins+ cells, which wasreversed by the addition of DPD. In contrast, the addition
of a cell-permeable cAMP analog, dibutyryl cAMP (dBu-
cAMP) increased the number of Ins+ cells; however, this
was not affected by the addition of dopamine, indicating
that cAMP is likely downstream of dopamine. These results
suggested that dopamine functions to negatively regulate
b cell proliferation and promote cell death by decreasing
cAMP levels through DRD2 (Figure 2H).
DPD Treatment Protects b Cells from
Dedifferentiation and Increases b Cell Mass
In our islet dissociation culture, we observed an increase in
the proportion of ‘‘other’’ cells that were not stained with
the antibodies tested. DPD treatment resulted in an in-
crease in Ins+ cells and simultaneous decrease in ‘‘other’’
cells (Figure 2D). The results thus urged us to hypothesize
that b cell dedifferentiation occurs, so that ‘‘other’’ cellsStem Cell Reports j Vol. 7 j 95–109 j July 12, 2016 97
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that represent dedifferentiated b cells increase, and that
DPD might protect b cells from dedifferentiation. To test
this possibility, we used islets harvested from mice bearing
both Ins2-Cre (RIP-Cre) and Rosa26-loxP-Stop-loxP-EYFP
transgenes, in which b cells that once expressed insulin
would be labeled permanently with EYFP (Figure 3A). If
b cell dedifferentiation occurs during dissociation culture,
the EYFP-labeled Ins+ b cells would turn into Ins-negative
(Ins) cells. As a result, we found that dedifferentiation of
b cells actually occurred. On day 3 after dissociation,
many EYFP+/Ins+ cells were observed. By contrast, on day
5, the ratio of EYFP+/Ins+ cells decreased and EYFP+/Ins–
cells increased. DPD addition rescued the reduction of
EYFP+/Ins+ cells and prevented the increase of Ins–/EYFP
dedifferentiated cells, whereas dopamine addition acceler-
ated the reduction of EYFP+/Ins+ cells (Figure 3B).
We further assayed for EdU incorporation and apoptosis.
Our results revealed that proliferation was observed in
EYFP+/Ins+ b cells, but not in the dedifferentiated EYFP+/
Ins– cells (Figures 3C–3E0). EdU incorporation revealed that
DPD promoted proliferation of the differentiated b cells
(Ins+/EYFP+ cells), but not the dedifferentiated b cells (Ins/
EYFP+ cells). Dopamine decreased proliferation of the Ins+/
EYFP+ b cells (Figure 3F). Caspase-3/7 staining revealed that
apoptosis was detected mainly in the Ins+/EYFP+ b cells but
not in the dedifferentiated Ins–/EYFP+ cells. DPD protected
and dopamine increased apoptosis of the Ins+/EYFP+ b cells
(Figures 3G–3I0, 3J). The dedifferentiated b cells showed
low adherence properties and tended to detach from plates;
therefore, their cell numbers might be underestimated (Fig-
ure 2D, ‘‘other’’ cells and Figure 3, green bars).
Taken together, our results revealed that b cell dediffer-
entiation is the major mechanism for b cell loss that oc-
curs during islet dissociation culture, which is mediated
through dopamine signaling. Inhibition of dopamine
signal increased b cell number mainly through the mainte-
nance of the differentiated state of b cells, although its ef-
fects on decreasing apoptosis and increasing proliferation
of b cells also account for the increased b cell mass.Figure 3. DPD Protects Pancreatic b Cells from Dedifferentiation a
In Vitro Dissociation Culture
The effects of DPD and dopamine (DA) in dedifferentiating b cells.
(A) R26-EYFP homozygote (+/+) and RIP-cre homozygote (+/+) m
generated.
(B) The dissociated islet cells were cultured, and applied with differen
observed in control (DMSO)-, DPD-, or dopamine-containing culture
dedifferentiated cells.
(C–F) DPD treatment (days 3–5) (C–E0) increased EdU (labeled on da
dedifferentiated cells (Ins–/EYFP+, green bars).
(G–J) DPD treatment (days 3–5) (G–I0) reduced caspase-3/7+ cells in
Data represent mean ± SD. All data are obtained from three to fo
**p < 0.01, *p < 0.05, Student’s t test. Scale bar represents 50 mm.Loss-of-Function and Gain-of-Function Studies of the
Role of Dopamine-DRD2 Signaling in Regulating Cell
Number and Apoptosis in MIN6 Cells
To examine the function of dopamine signaling in detail
we used MIN6 cells, a b cell line. The number of MIN6 cells
increased in cultures treated with DPD or dBu-cAMP. By
contrast, dopamine treatment decreased the number of
MIN6 cells (Figure 4A). DPD treatment increased prolifera-
tion assayed by EdU incorporation (Figure 4B). These re-
sults in MIN6 cells phenocopied those observed in our
primary islet culture. We then assayed intracellular cAMP
levels after various chemical treatments. DPD increased
cAMP levels whereas dopamine decreased cAMP levels.
When DPD was added together with dopamine, the dopa-
mine-mediated decrease in cAMP was reversed (Figure 4C).
Taken together, our results strongly suggest that MIN6 pro-
liferation is mediated by cAMP signaling and that dopa-
mine activates DRD2, decreases intracellular cAMP levels,
and reduces the number of MIN6 cells.
We then established a Drd2-knockdown (D2KD) MIN6
cell line by introducing a D2shRNA-mRFP construct, in
which D2shRNA expression could be monitored as mRFP
expression (Figure 4D). The D2KD MIN6 cell lines showed
that Drd2 expression was approximately 40% that of the
wild-type MIN6 cells (Figure 4E). Cell number was signifi-
cantly increased in D2KD MIN6 cells, to a level similar to
that of the DPD-treated control vector-introduced non-
silencing (NS) cells (Figure 4F). DPD treatment did not
further increase the number of D2KDMIN6 cells. However,
due to the partial knockdown of Drd2 in D2KDMIN6 cells,
dopamine treatment still inhibited cell proliferation, but to
a lesser degree than that in the vector-transfected control
MIN6 cells (Figure 4F, NS). The addition of dBu-cAMP to
the D2KDMIN6 cells did not further increase cell numbers,
suggesting that inD2KDMIN6 cells, cAMPmediates the in-
crease in cell number. Taken together, the results show that
in MIN6 cells, treatment with DPD increased cell numbers
by antagonizing dopamine signaling through DRD2, and
that dopamine negatively regulates cell proliferation bynd Thus Enhances Proliferation and Decreases Apoptosis during
ouse were crossed and RIP-Cre(+/)/R26-EYFP(+/) mice were
t chemicals on days 3–5. Dedifferentiated b (Ins–/EYFP+) cells were
conditions, assayed on day 5. DPD treatment reduced Ins–/EYFP+
ys 3–5) incorporation in Ins+/EYFP+ cells (golden bars), but not in
Ins+/EYFP+ cells (golden bars).
ur independent experiments, each with three to four replicates.
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Figure 4. Loss-of-Function and Gain-of-Function Studies of the Dopamine D2 Receptor DRD2 in MIN6 Cells
The effects of DPD and dopamine (DA) in control (A, B, C, G) and Drd2-knockdown (D, E, F) or Drd2-overexpressing (H, I) MIN6 cells.
(A) The number of MIN6 cells per well after 4 days of chemical treatment (days 3–7). Dopamine treatment decreased the number of cells,
whereas DPD or cAMP treatment increased the number of MIN6 cells (five independent experiments, each with three to six replicates).
(B) DPD increased proliferation of MIN6 cells revealed by EdU incorporation (48 hr) assay (four independent experiments, each with four
replicates).
(C) Relative cAMP levels after 6 hr of chemical treatment on day 3. DPD increased intracellular cAMP levels, whereas dopamine decreased
intracellular cAMP levels, and DPD reversed the dopamine-mediated decrease.
(D–F) Drd2 knockdown increased cAMP levels and phenocopied DPD effects. (D) Upper panel: a schematic of the lentiviral vector used
for Drd2 shRNA-mRFP expression. Lower panel: fluorescence and transmission images of the Drd2-knockdown MIN6 cells (D2KD). (E) D2KD
(legend continued on next page)
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decreasing cAMP levels through DRD2. In D2KD MIN6
cells, this negative regulation is shut down, mimicking
the effects of DPD.
We then examined dopamine-dependent apoptosis in
MIN6cells.Dopaminedose-dependently induced apoptosis,
and approximately 6.5%ofMIN6 cells underwent apoptosis
in the presence of 10 mMdopamine (Figure 4G). The expres-
sion of Bcl2, an anti-apoptotic gene, was downregulated
upondopamine treatment andupregulated uponDPD treat-
ment. In contrast, the expression of Bax, a pro-apoptotic
gene, was downregulated upon DPD treatment (Figure S3).
These results suggest that dopamine treatment increased
apoptosis, whereas DPD treatment inhibited apoptosis
through regulating Bcl2 and Bax expressions.
We next examined the effects of overexpressing Drd2 in
MIN6 cells. MIN6 cells transfected withD2-3Flag expressed
much higher levels of Drd2 than the control vector-trans-
fected cells (Figure 4H). The effects of dopamine treatment
were compared between the Drd2-overexpressing and con-
trol MIN6 cells. Drd2-overexpressing MIN6 cells showed a
dopamine dose-dependent increase in apoptosis because
of their increased sensitivity to dopamine. Up to 37% of
cells became apoptotic following treatment with 10 mM
dopamine. Comparedwith control cells,Drd2-overexpress-
ing cells showed an approximately 5-fold increase in
apoptosis (Figure 4I). These results suggest that dopamine
is an apoptotic signal and that overexpression of Drd2
increased sensitivity to the signal.
Dopamine Modulates b Cell Proliferation by Acting as
an Inhibitory Signal for Adenosine
The adenosine signaling pathway has been reported to be a
potent signal for b cell regeneration (Andersson et al.,
2012). The adenosine agonist 50-N-ethylcarboxamidoade-
nosine (NECA), which acts through the adenosine receptor
A2a (ADORA2A), was reported to increase b cell prolifera-
tion. ADORA2A is a GPCR that is known to mediate Gas
signaling to activate adenylyl cyclase and increase intracel-
lular cAMP. ADORA2A and DRD2 have been reported to be
highly co-localized and to form heterodimers (Canals et al.,
2003).
To gain insight into the relationship between adenosine
signaling and dopamine function in terms of b cell prolif-cells showed a partial decrease in Drd2 expression (two independent e
to dopamine chemicals. DPD increased cell number for 9 days cult
knockdown cells (four independent experiments, each with four repli
(G–I) Dopamine treatment of wild-type (G) or Drd2-overexpressing (I)
number of apoptotic cells (G) (three independent experiments, each
FLAG-tagged Drd2-expressing vector, and lower panel shows RT-PCR a
cells overexpressing Drd2 (D2-OE) showed increased sensitivity to dopa
10 mM dopamine (I) (three independent experiments, each with thre
treated cells. Data represent mean ± SD. Student’s t test. Scale bar, 1eration, we examined the possible interaction between
ADORA2A and DRD2. Duolink in situ proximity ligation
assays revealed that DRD2 and ADORA2A are expressed
and form a heterodimer in dissociated mouse pancreatic
b cells (Figures 5A–A00). The interaction of DRD2 and
ADORA2A was further confirmed by co-immunoprecipita-
tion with antibodies against ADORA2A and DRD2 (Fig-
ure 5B). DRD2-ADORA2A heterodimer formation was
enhanced by dopamine but suppressed by DPD or NECA
addition (Figures 5C–5G). The results suggest an inhibi-
tory effect of heterodimer formation against adenosine
signaling.
We then tested islet b cells using our primary culture sys-
tem (Figures 5H–5J). NECA alone increased the number of
b cells and reversed the negative effects of dopamine,
similar to the dopamine-inhibitory effect of DPD. NECA
was shown to increase EdU incorporation (proliferation)
of b cells and decrease apoptosis. Similar to DPD, NECA
effectively rescued the proliferation of dopamine-treated
b cells. However, NECA seemed to be less effective than
DPD for rescuing dopamine-triggered apoptosis (Figure 5J;
p = 0.06).
We also tested the effect of NECA in MIN6 cells (Fig-
ure S4A). Treatment with NECA or DPD alone increased
the number of MIN6 cells when present at R1.0 mM (D.S.
et al., unpublished data). At lower concentrations, DPD
and NECA work together to yield even more numbers
of MIN6 cells. Under Drd2 knocked-down background,
NECA was more effective in increasing cell number
compared with control wild-type MIN6 cells (Figure S4B).
These results suggest that a basal dopamine signal might
exert negative effects on ADORA2A -mediated b cell
proliferation.
Taken together, our results suggest that dopamine-DRD2
signaling negatively regulates proliferation and increases
apoptosis, through inhibition of adenosine-ADORA2A
signaling that positively regulates proliferation and reduces
apoptosis. DRD2 and ADORA2A form homo- or hetero-
dimer. We hypothesize that binding of dopamine to
DRD2 promotes DRD2-ADORA2A heterodimer formation,
through which dopamine negatively regulates adenosine-
ADORA2A signaling, and vice versa (Figure 5K). Integration
of these two signals is important for the regulation of b cellxperiments, each with three replicates). (F) Responses of D2KD cells
ure, but not in D2KD cells. The effect of dopamine decreased in
cates).
MIN6 cells on days 3–7. Dopamine dose-dependently increased the
with four replicates). Upper panel in (H) shows a schematic of the
nalysis of the exogenously overexpressed Drd2 in MIN6 cells. MIN6
mine. Up to 37% of the cells became apoptotic after treatment with
e replicates). **p < 0.01, *p < 0.05 compared with control DMSO-
00 mm.
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mass, and the differentiation versus dedifferentiation states
of b cells.DPD Is Also Effective in Human b Cells
We then tested the effects of DPD to examine whether a
similar mechanism could be applied to human islet b cells.
Human b cells from a single donor were dissociated and
subjected to assays for EdU incorporation and apoptosis.
With human islets, chemical treatments were done on
days 1–3 and assayed on day 3. We found that treatment
with DPD, dopamine + NECA, dBu-cAMP, or 5IT (iodotu-
bercidin), an adenosine kinase inhibitor, increased the
expression level of an anti-apoptotic protein BCL2 (Fig-
ure 6A). Although NECA alone did not induce BCL2
expression in the human b cells, it induced Bcl2 in the
mouse b cells (D.S., unpublished data). Expression of a
pro-apoptotic protein, BAX, was increased with dopamine
treatment (Figure 6B). DPD, NECA, DPD + NECA, dBu-
cAMP, or 5IT increased total Ins+ cell numbers and EdU
(24 hr) incorporation and reduced apoptosis, whereas
dopamine decreased total Ins+ cell number and EdU incor-
poration and increased apoptosis (Figures 6C–6E). Our re-
sults suggest that a similarmechanism exists in human islet
b cells and that dopamine acts as a negative regulator for
b cell mass. Dopamine inhibits proliferation and triggers
apoptosis, and inhibition of dopamine signal reduces
apoptosis and increases b cell number.DISCUSSION
Here, we utilized an adult islet dissociation culture system
to identify chemicals that promote b cell proliferation.
We revealed that in islet cell dissociation culture, b cell pro-
liferation was triggered and at the same time b cell loss dueFigure 5. Synergistic Effects of NECA, an ADORA2A Agonist, and
between DRD2 and ADORA2A
(A and B) DRD2 and ADORA2A are expressed and form heterodimer in d
and Duolink assay was performed immediately after dissociation. (B) C
(IP-D2), anti-ADORA2A (IP-A2A), or mouse IgG (mIgG) antibody were
D2), respectively. The results indicated that DRD2 and ADORA2A form
(C–G) DRD2-ADORA2A dimerization states detected by Duolink assay w
(C–F0). Dissociated islet cell cultures on day 3 were treated with chem
heterodimer formation was suppressed by DPD or NECA, and enhance
(H–J) The effect of NECA on b cell proliferation was examined using isl
chemical treatment (days 3–7) were counted and was increased by NEC
cells was reversed by treatment with NECA or DPD. (I) The number of Ed
7) were counted. EdU incorporation (48 hr) in b cells was increased
treatment with NECA or DPD. (J) b cell apoptosis was assessed after 2
cells was decreased by treatment with NECA or DPD. Dopamine-trigge
(K) Schematic of crosstalk between dopamine-DRD2 and adenosine-AD
All data are obtained from three independent experiments, each with
bars), Student’s t test.to apoptosis and dedifferentiation of b cells was observed.
Therefore, our islet cell dissociation culture system might
represent a state seen in type 1 or type 2 diabetes, where
disruption of cell-cell communication between islet cells
promotes b cells to trigger failures in maintaining their
identities and undergo apoptosis. Utilizing this assay sys-
tem, we identified DPD, an antagonist of DRD2 signaling,
as a chemical that specifically increased b cell mass by
antagonizing dopamine signaling. Dedifferentiation of
b cells seems to contribute to the major part of b cell
loss in our present islet dissociation culture. Dopamine
signaling, which is mediated by DRD2, decreases cAMP
and triggers dedifferentiation and apoptosis of b cells.
Antagonizing dopamine signaling by adding DPD pro-
tected b cells from dedifferentiation, apoptosis, and
increased proliferation.
In MIN6 cells, Drd2 knockdown increased cell number.
Therefore, dopaminemight function as an autocrine inhib-
itor produced from b cells themselves. Activation of dopa-
mine signaling through DRD2 seems to be a default state
for b cells to inhibit proliferation, so that removal of the
dopamine signal might be necessary for re-entry into the
cell cycle. Dopamine has been reported to modulate prolif-
eration and apoptosis of Ins+ cells (Garcia Barrado et al.,
2015; Garcia-Tornadu et al., 2010). These previous reports
and our present results provide strong evidence for the
importance of dopamine signaling in regulating b cell
mass. MIN6 cells treated with DPD showed higher cAMP
levels, suggesting that DPD enhanced proliferation by
regulating cAMP. Importantly, we further revealed that
DPD also increased Ins+ cell number and proliferation,
and decreased apoptosis in human islet b cells. Therefore,
the mechanism found in mice also functions in humans.
There are five different dopamine receptor subtypes, one
of which, DRD2, is expressed in pancreatic b cells ofDPD on b Cell Proliferation and Cell Death through Interaction
issociated mouse pancreatic b cells. (A–A00) Islets were dissociated
o-immunoprecipitates of the dissociated islet cells using anti-DRD2
immunoblotted with anti-ADORA2A (IB-A2A) or anti-DRD2 Ab (IB-
ed a heterodimer.
ere changed by dopamine (DA), DPD, or NECA, an ADORA2A agonist
icals for 6 hr and subjected to Duolink assay. (G) DRD2-ADORA2A
d by dopamine.
et dissociation cultures. (H) The number of Ins+ cells after 4 days of
A treatment. The dopamine-mediated reduction in the number of b
U+ among the Ins+ cells after 4 days of chemical treatment (days 3–
by NECA treatment. Decreased b cell proliferation was reversed by
days of chemical treatment (days 3–5). The number of apoptotic b
red apoptosis was rescued by DPD but not by NECA.
ORA2A through heterodimer formation. Data represent mean ± SD.
three replicates. **p < 0.01, *p < 0.05 compared with control (open
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Figure 6. DPD and NECA Promoted Proliferation and Suppressed Cell Death in Human b Cells
(A and B) The effects of dopamine (DA) and adenosine signaling were tested in human primary culture by treating human islet cells with
chemicals on days 1–3, and assayed on day 3. DPD, NECA, dBu-cAMP, and 5-iodotubericidin (5IT), an inhibitor of adenosine kinase,
increased the expression level of BCL2 (A), whereas dopamine increased the expression of BAX (B) in human islet cells.
(C) Total cell number per well, showing the number of Ins+ cells increased by adding DPD, NECA, DPD + NECA, cAMP, or 5IT.
(D) EdU incorporation assayed for 24 hr. DPD, NECA, cAMP, and 5IT increased EdU incorporation whereas dopamine decreased EdU
incorporation in human b cells.
(E) Dopamine promoted apoptosis, whereas DPD, NECA, cAMP, and 5IT decreased apoptosis. Data represent mean ± SD. Data are from a
single donor and each point represents three replicates. **p < 0.01, *p < 0.05 compared with control (open bars), Student’s t test.humans and rodents (Rubi et al., 2005; Ustione and Piston,
2012). In the pancreas, dopamine is reported to function
through the DRD2 receptor as an inhibitory signal against
insulin secretion. In b cells, dopamine is synthesized from
circulating L-Dopa, which is produced by the gastrointes-
tinal tract (Ustione et al., 2013). Knockdown of DRD2 in
INS-1 cells (a b cell line) resulted in increased insulin secre-
tion (Wu et al., 2008). However, globalDrd2-knockoutmice104 Stem Cell Reports j Vol. 7 j 95–109 j July 12, 2016showed impaired insulin secretion, which caused glucose
intolerance (Garcia-Tornadu et al., 2010). Since dopamine
is reported to regulate insulin secretion, we then tested
whether insulin affects b cell proliferation or cell death in
our culture, and found that insulin at high concentration
(>100 nM) inhibited b cell proliferation regardless of DPD
(Figure S5A). Insulin also promoted apoptosis at low con-
centrations, which was not rescued by DPD treatment
(Figure S5B). We interpret the seemingly contradictory pre-
vious reports and our results tomean that the insulin signal
is toxic for b cells and that the inhibitory dopamine signal
against insulin secretionmight be important for protecting
b cells from a high workload. The inhibitory effects of the
dopamine signal on b cell proliferationmight also function
as a brake. Determining how the dopamine signal is regu-
lated is important for understanding its action.
Recently, we found that vesicular monoamine trans-
porter 2 (VMAT2) regulates monoamine (including dopa-
mine) storage by acting as a negative regulator, such that
high monoamine levels inhibit the progression from
Pdx1+ pancreatic progenitor cells to Neurog3+ endocrine
progenitor cells of ESC-derived pancreatic progenitor cells
and during embryonic pancreatic development (Sakano
et al., 2014). VMAT2, which regulates dopamine storage,
and tyrosine hydroxylase, which synthesizes dopamine,
are expressed in both the embryonic pancreas and the
adult islets (Persson-Sjogren et al., 2002; D.S. et al., unpub-
lished data). Our results suggest that the VMAT2-dopamine
signal plays important roles both during pancreas develop-
ment and in the maintenance of b cell mass.
It was previously reported that NECA promotes b cell
regeneration in a zebrafish model and that adenosine ki-
nase inhibitors increase primary b cell proliferation (Annes
et al., 2012). We found that NECA functions by antago-
nizing dopamine signaling to increase b cell proliferation
and decrease b cell apoptosis.
The detailed mechanism of the crosstalk between
ADORA2A and DRD2 signaling in b cell proliferation
is not yet known. Adenosine signaling is mediated by
ADORA2A, which is a Gas-coupled receptor that increases
cAMP. Dopamine signaling is mediated by a Gai-coupled
receptor DRD2, which decreases cAMP. Thus, ADORA2A
and DRD2 exert opposing effects on cAMP levels, and
they have been reported to be highly co-localized and
form heterodimers in the striatum (Fuxe et al., 2001)
and neuronal cells (Kamiya et al., 2003) where the hetero-
dimer antagonizes homodimer formation of ADORA2A/
ADORA2A or DRD2/DRD2, to modulate dopaminergic ac-
tivity (Ferre et al., 1991; Hall and Strange, 1999). L-Dopa
treatment, which activates dopamine signaling, was
reported to disrupt heteromer formation (Bonaventura
et al., 2014; Pinna et al., 2014).
Crosstalk between adenosine and dopamine signaling
through other mechanisms has also been observed.
ADORA2A mediates the phosphorylation of dopamine-
and cAMP-regulated phosphoprotein of Mr 32,000
(DARPP-32) at Thr34 (the cAMP-dependent protein kinase
site) in striatopallidal neurons, and has been reported
to oppose DRD2 signaling (Shuto et al., 2006; Yabuuchi
et al., 2006). Similarly, dopamine signaling has been
reported to exert opposing effects on GLP-1 throughphosphorylation of the serine/threonine kinase AKT, its
downstream substrate GSK3b, and several other down-
stream signaling molecules (Ustione et al., 2013).
Our results, showing that activation of the adenosine
signaling pathway byNECA together withDPD application
in MIN6 cells and islet b cells further increased cell
numbers compared with their single applications, thereby
suggest that DRD2 and ADORA2A signal via different path-
ways. This notion is supported by the ability of NECA
to overcome dopamine-dependent cell loss and the dopa-
mine-dependent decrease in b cell proliferation. Our results
suggest that dopamine inhibits adenosine signaling at least
in part through ADORA2A-DRD2 heterodimer formation,
so that ADORA2A receptor cannot activate downstream
signaling events. However, it remains unknown how
heterodimerization acts on cAMP levels and how it affects
downstream signaling events.
In conclusion, the present study revealed the role of
dopamine signaling in the control of b cell proliferation
and apoptosis, and the maintenance of b cell differentia-
tion; dopamine acts through DRD2 to decrease cAMP.
Dopamine also functions through negatively regulating
other signaling pathways such as the adenosine pathway.
Our finding could be beneficial for the development of
new targets for increasing b cell mass.EXPERIMENTAL PROCEDURES
Animals
RIP-Cre (Postic et al., 1999) and Rosa26-EYFP (Srinivas et al., 2001)
have been previously described. All animal procedures were per-
formed in accordance with the guidelines for the care and use
of animals of Kumamoto University and Tokyo Institute of
Technology.Chemicals
DPD and NECAwere purchased from Tocris Bioscience. dBu-cAMP
was purchased from BIOMOL International. Dopamine was ob-
tained from LKT Laboratories. 5IT was purchased from Toronto
Research Chemicals. Test compounds were dissolved in DMSO
and were added to cells on day 3 and assayed on day 5, unless
otherwise indicated. Final concentrations of the chemicals used
were: 0.5 mMDPD, 0.25 mMNECA, 1.0 mMdBu-cAMP, 1.0 mMdopa-
mine, and 1.0 mM 5IT unless otherwise indicated.Islet Isolation and Screening Culture
Mouse islets from 10-week-old C57BL/6 mice (SLC) and RIP-Cre/
R26-eYFP mice were isolated as described previously (Kikawa
et al., 2014). Isolated islets were handpicked and dissociated into
single cells by incubation with 0.05% trypsin-EDTA (Invitrogen)
for 5 min at 37C and 5% CO2 and pipetting. The dissociated cells
were plated in 96-well plates at a density of 2,000 cells per well in
DMEM supplemented with 10% fetal bovine serum, 100 mM non-
essential amid acids, 2 mM L-glutamine, 50 units/ml penicillin,Stem Cell Reports j Vol. 7 j 95–109 j July 12, 2016 105
50 mg/ml streptomycin, and 100 mM 2-mercaptoethanol (Sumi-
tomo Bakelite).
EdU Incorporation
Cells were incubated in culturemedium containing 20 mMEdU for
48 hr prior to harvest (days 3–5), unless otherwise indicated, then
processed using the Click-iT EdU Alexa Fluor 594 Imaging Kit
(Invitrogen), and stained with DAPI and anti-insulin antibodies.
Screening of Small Molecules and Quantitative
Imaging Analysis
Small molecules from the bioactive, pharmacologically defined
Prestwick Chemical Library were screened for pro-differentiation
activity. Compounds were dissolved in DMSO and added at a
1:100 dilution on day 3. Cells were assayed by immunostaining
with an anti-insulin antibody on day 5. Fluorescent images were
quantified by counting the number of pixels, representing the
number of positive cells, using an ImageXpress micro scanning
system andMetaXpress cellular image analysis software (Molecular
Devices). Data are reported as the relative fold changes normalized
to the DMSO-only controls. A hit compound was defined as a
compound causing a 2-fold or higher increase in the number of
EdU-positive insulin-positive b cells. Candidate compounds were
tested for dose dependency and reproducibility.
Apoptosis Assay
For the apoptosis assay, caspase-3/7 activity was measured using
CellEvent Caspase-3/7 Green Detection Reagent (Invitrogen Life
Technologies) according to the manufacturer’s protocol.
Immunocytochemistry
Cells were fixed with 4% paraformaldehyde for 30 min. The
following antibodies were used: guinea pig anti-insulin (A0564,
Dako Denmark; 1:500), mouse anti-glucagon (G2654, Sigma-
Aldrich; 1:500), rabbit anti-DRD2 receptor (251384, ABBIOTEC;
1:500), rabbit anti-GFP (598, Medical & Biological Laboratories;
1:1,000), Alexa 488 goat anti-rabbit immunoglobulin G (IgG)
(A-11008 Life Technologies; 1:1,000), Alexa 568 goat anti-guinea
pig IgG (A-11075, Life Technologies; 1:1,000), and Alexa 647
goat anti-mouse IgG (A-21235, Life Technologies; 1:1,000). Cells
were counterstained with DAPI (Roche Diagnostics; 1:1,000).
Mouse anti-ADORA2A, clone 7F6-G5-A2 (ab115250, Abcam;
1:500) was obtained from Millipore.
Real-Time PCR Analysis
RNA was extracted from cells using the RNeasy mini-kit (Qiagen)
and treated with DNase I (Qiagen). cDNA was synthesized from
1 mg of total RNAusing Revertra Ace qPCRRTMasterMix (Toyobo).
For the real-time PCR analysis, mRNA expression was quantified
by amplification in an ABI 7500 thermal cycler (Applied Bio-
systems) with SYBR Green. Gene expression of target genes was
normalized to that of b-actin. The PCR conditions were as follows:
denaturation at 95C for 15 s and annealing and extension at 60C
for 60 s, for up to 40 cycles. Each measurement was normalized to
b-actin (mouse) or GAPDH (human) by subtracting the average
b-actin or GAPDH expression level. Target mRNA levels were ex-106 Stem Cell Reports j Vol. 7 j 95–109 j July 12, 2016pressed as a.u. and were determined using the standard curve
method. All primers used for real-time PCR are listed in Table S1.
Gene Silencing
For the Drd2-knockdown assays, cells were transfected with either
Expression Arrest, non-silencing, control short hairpin RNA
(shRNA) (Open Biosystems; #RHS4080) orDrd2 shRNA (Open Bio-
systems; #TRCN0000025738). The lentiviral vectors were con-
structed as previously described (Golla and Seethala, 2002), and
MIN6 cells were infected with viral supernatants. After a 24-hr
incubation, the virus-containing medium was replaced with fresh
ESC maintenance medium. After another 24 hr incubation, in-
fected cells were selected by the addition of 1.5 mg ml1 puromy-
cin. The surviving cells were harvested, and clones were selected
to establish knockdown and control cell lines.
Drd2 Overexpression
A cDNA fragment of mouse Drd2 (nucleotides 95–1,429; NM_
010077.2; amino acids 1–444) was inserted into the XhoI–BamHI
sites of the pCDNA3-cFlag vector (Addgene). MIN6 cells were
plated at 4 3 104 cells per well in 96-well culture plates on the
day of transfection (0.3 mg of plasmid DNA). DNA was mixed
with Opti-MEM medium (Life Technologies) containing Hilymax
(Dojin) at a ratio of 3:1 to total DNA and then added to the cells.
cAMP Content Measurement
cAMP levels were calculated using the cAMP-Glo Assay (Promega)
following themanufacturer’s protocol 36. In brief, MIN6 cells were
grown in 96-well plates and lysed with the buffer provided in the
kit. Intracellular cAMP levels were detected using the detection so-
lution provided in the kit. Luminescence was measured using a
GloMax 96 Microplate Luminometer (Promega). A standard curve
was generated in parallel for each experiment using serial dilutions
of the cAMP standard provided with the kit.
Co-immunoprecipitation and Western Blot Analysis
Co-immunoprecipitationwasperformedusing rabbit anti-DRD2 re-
ceptor antibody (251384, ABBIOTEC) or mouse monoclonal [7FG-
G5-A2] against ADORA2A (ab115250, Abcam). In brief, mouse islet
cells were lysed with RIPA buffer (50 mM Tris [pH 7.4], 150 mM
NaCl, 1%NP-40, 0.1%SDS, 1.5mMMgCl2) and the cellular extracts
were incubated for 16 hr with the antibody coupled to Protein A/G
PLUS-Agarose beads (Santa Cruz Biotechnology, #sc-2003) at 4C
under rotation. Immunoprecipitates were spun down and washed
six times in RIPA buffer. Co-immunoprecipitates were dissolved
with 23 Laemmli buffer and boiled for 5 min for SDS-PAGE.
SDS-PAGE was carried out using an 8% acrylamide gel. Western
blot analysis of DRD2 or ADORA2A after co-immunoprecipitation
was carried out on polyvinylidene fluoride membranes using pri-
mary antibody and Immuno-Aptamer rabbit IgG (Nippon Gene,
310-07,211) or mouse IgG (Nippon Gene, 310-07,201) dissolved
in TBST-Mg (Tris-buffered saline containing 0.05% Tween 20 and
5 mM MgCl2) containing 1% acetylated BSA (Nippon Gene, 316-
07,291). After washing with TBST (TBS containing 0.05% Tween
20), the membrane was incubated with TBST containing streptavi-
din-horseradish peroxidase conjugate (1:10,000; Perkin Elmer,
#NEL750001EA) antibody. Finally the membrane was reacted
with ECL Prime reagents (GE Healthcare) and scanned using a
Fusion Solo (Vilber-Lourmat) imaging system.
Duolink In Situ Proximity Ligation Assay
Direct protein-protein interactions were investigated by means of
a proximity ligation assay (PLA) (Soderberg et al., 2006) using Du-
olink In Situ Red Starter Kit Mouse/Rabbit (Sigma). Dispersed islet
cells were washed with PBS and then either immediately fixed, or
cultured for 3 days and treated with chemicals for 6 hr then fixed
on the culture dish at room temperature for 30 min in 4% parafor-
maldehyde, for further use in Duolink PLA. Cells were further
rinsed for 10 min with PBS containing 1% Triton X-100 (Sigma)
and then washed for 10 min three times with 0.05% Tween 20 in
PBS to allow permeabilization. Duolink II blocking solution was
then added into wells, followed by incubation for 1 hr at room
temperature. The blocking solution was then tapped off and cells
were incubated for 1 hr at 37C with primary antibodies. Primary
antibodies used were: rabbit anti-DRD2 receptor antibody (1:500;
ABBIOTEC, #251384) or mouse monoclonal (7FG-G5-A2) to
ADORA2A (1:500; Abcam, #ab79714). Duolink anti-rabbit PLUS
and anti-mouseMINUS secondary antibodies and red detection re-
agents were used and antibody incubation, ligation, amplification,
and washing steps were performed according to the supplier’s
manual. Cells were then immunocytochemically stained with
anti-insulin antibody and DAPI. The average intensity of PLA sig-
nals in insulin-positive cell areawas calculated byMetaMorph soft-
ware (Molecular Devices).
Human Islets
Non-diabetic human islets were obtained from Prodo Laboratories,
and cultured in Prodo Islet Medium (Prodo Laboratories). Donor
information is as follows. Age, 56; gender, female; ethnicity, Afri-
can American; body mass index, 33.4; diabetes, no history; and
hemoglobin A1c, 5.2%. Chemicals were added on days 1–3 after
dissociation, considering the islets used were not freshly isolated
(more than 1 week after isolation).
Statistics
Data are expressed as the mean ± SD. Differences between groups
were analyzed by Student’s t test. A p value of less than 0.05 was
considered statistically significant. Data were confirmed in three
to four independent experiments for reproducibility, each experi-
ment with three to six biological replicates, unless otherwise
indicated.
SUPPLEMENTAL INFORMATION
Supplemental Information includes five figures and one table and
can be found with this article online at http://dx.doi.org/10.1016/
j.stemcr.2016.05.015.
AUTHOR CONTRIBUTIONS
D.S., N.S., and S.K. conceived the project and designed the study;
D.S., S.C., and M.K. performed most experiments; M.U. provided
the chemical library; D.S., N.S., M.U., K.K., and S.K. contributed
to data analysis and interpretation; D.S. and S.K. wrote the paper;
all the authors approved the final version of the manuscript.ACKNOWLEDGMENTS
We thankMr. Yuki Sonoda andMs.Misako Katabuchi for technical
assistance and helpful discussions, and Dr. Junji Hirota and the
members of the Center for Biological Resources and Informatics
at Tokyo Institute of Technology, and the members in the Center
for Animal Resources and Development at Kumamoto University
for their technical assistance. This work was supported by
grants (26253059 and 26670384 to S.K., 26461638 to N.S., and
26461036 to D.S.) from theMinistry of Education, Culture, Sports,
Science and Technology (MEXT) Japan. This work was also sup-
ported in part by the Takeda Science Foundation, Japanese Insulin
Dependent Diabetes Mellitus (IDDM) Network Foundation, and
the Program for Leading Graduate Schools ‘HIGO’ to Kumamoto
University from MEXT. S.K. is a member of the HIGO Program,
MEXT, Japan.
Received: August 18, 2015
Revised: May 27, 2016
Accepted: May 31, 2016
Published: June 30, 2016REFERENCES
Andersson, O., Adams, B.A., Yoo, D., Ellis, G.C., Gut, P., Anderson,
R.M., German,M.S., and Stainier, D.Y. (2012). Adenosine signaling
promotes regeneration of pancreatic beta cells in vivo. Cell Metab.
15, 885–894.
Annes, J.P., Ryu, J.H., Lam, K., Carolan, P.J., Utz, K., Hollister-Lock,
J., Arvanites, A.C., Rubin, L.L., Weir, G., and Melton, D.A. (2012).
Adenosine kinase inhibition selectively promotes rodent and
porcine islet beta-cell replication. Proc. Natl. Acad. Sci. USA 109,
3915–3920.
Baeyens, L., De Breuck, S., Lardon, J., Mfopou, J.K., Rooman, I., and
Bouwens, L. (2005). In vitro generation of insulin-producing beta
cells from adult exocrine pancreatic cells. Diabetologia 48, 49–57.
Bernal-Mizrachi, E., Kulkarni, R.N., Scott, D.K., Mauvais-Jarvis, F.,
Stewart, A.F., and Garcia-Ocana, A. (2014). Human beta-cell prolif-
eration and intracellular signaling part 2: still driving in the dark
without a road map. Diabetes 63, 819–831.
Bonaventura, J., Rico, A.J., Moreno, E., Sierra, S., Sanchez, M., Lu-
quin, N., Farre, D., Muller, C.E., Martinez-Pinilla, E., Cortes, A.,
et al. (2014). L-DOPA-treatment in primates disrupts the expres-
sion of A(2A) adenosine-CB(1) cannabinoid-D(2) dopamine recep-
tor heteromers in the caudate nucleus. Neuropharmacology 79,
90–100.
Bonner-Weir, S., Li, W.C., Ouziel-Yahalom, L., Guo, L., Weir, G.C.,
and Sharma, A. (2010). Beta-cell growth and regeneration: replica-
tion is only part of the story. Diabetes 59, 2340–2348.
Canals, M., Marcellino, D., Fanelli, F., Ciruela, F., de Benedetti, P.,
Goldberg, S.R., Neve, K., Fuxe, K., Agnati, L.F., Woods, A.S., et al.
(2003). Adenosine A2A-dopamine D2 receptor-receptor heterome-
rization: qualitative and quantitative assessment by fluorescence
and bioluminescence energy transfer. J. Biol. Chem. 278, 46741–
46749.
Cano, D.A., Rulifson, I.C., Heiser, P.W., Swigart, L.B., Pelengaris, S.,
German, M., Evan, G.I., Bluestone, J.A., and Hebrok, M. (2008).Stem Cell Reports j Vol. 7 j 95–109 j July 12, 2016 107
Regulated beta-cell regeneration in the adult mouse pancreas. Dia-
betes 57, 958–966.
Collombat, P., Xu, X., Ravassard, P., Sosa-Pineda, B., Dussaud, S.,
Billestrup, N., Madsen, O.D., Serup, P., Heimberg, H., and Man-
souri, A. (2009). The ectopic expression of Pax4 in the mouse
pancreas converts progenitor cells into alpha and subsequently
beta cells. Cell 138, 449–462.
De Breuck, S., Lardon, J., Rooman, I., and Bouwens, L. (2003). Ne-
trin-1 expression in fetal and regenerating rat pancreas and its
effect on themigration of human pancreatic duct and porcine islet
precursor cells. Diabetologia 46, 926–933.
De Breuck, S., Baeyens, L., and Bouwens, L. (2006). Expression and
function of leukaemia inhibitory factor and its receptor in normal
and regenerating rat pancreas. Diabetologia 49, 108–116.
Dor, Y., Brown, J., Martinez, O.I., and Melton, D.A. (2004). Adult
pancreatic beta-cells are formed by self-duplication rather than
stem-cell differentiation. Nature 429, 41–46.
Ferre, S., von Euler, G., Johansson, B., Fredholm, B.B., and Fuxe, K.
(1991). Stimulation of high-affinity adenosine A2 receptors de-
creases the affinity of dopamine D2 receptors in rat striatal mem-
branes. Proc. Natl. Acad. Sci. USA 88, 7238–7241.
Finegood, D.T., Weir, G.C., and Bonner-Weir, S. (1999). Prior strep-
tozotocin treatment does not inhibit pancreas regeneration after
90% pancreatectomy in rats. Am. J. Physiol. 276, E822–E827.
Fuxe, K., Stromberg, I., Popoli, P., Rimondini-Giorgini, R., Torvi-
nen, M., Ogren, S.O., Franco, R., Agnati, L.F., and Ferre, S. (2001).
Adenosine receptors and Parkinson’s disease. Relevance of antago-
nistic adenosine and dopamine receptor interactions in the stria-
tum. Adv. Neurol. 86, 345–353.
Garcia-Tornadu, I., Ornstein, A.M., Chamson-Reig, A., Wheeler,
M.B., Hill, D.J., Arany, E., Rubinstein, M., and Becu-Villalobos, D.
(2010). Disruption of the dopamine d2 receptor impairs insulin
secretion and causes glucose intolerance. Endocrinology 151,
1441–1450.
Garcia Barrado, M.J., Iglesias Osma, M.C., Blanco, E.J., Carretero
Hernandez, M., Sanchez Robledo, V., Catalano Iniesta, L., Carrero,
S., and Carretero, J. (2015). Dopamine modulates insulin release
and is involved in the survival of rat pancreatic beta cells. PLoS
One 10, e0123197.
Golla, R., and Seethala, R. (2002). A homogeneous enzyme frag-
ment complementation cyclic AMP screen for GPCR agonists.
J. Biomol. Screen. 7, 515–525.
Hall, D.A., and Strange, P.G. (1999). Comparison of the ability of
dopamine receptor agonists to inhibit forskolin-stimulated adeno-
sine 3050-cyclic monophosphate (cAMP) accumulation via D2L
(long isoform) and D3 receptors expressed in Chinese hamster
ovary (CHO) cells. Biochem. Pharmacol. 58, 285–289.
Kamiya, T., Saitoh, O., Yoshioka, K., and Nakata, H. (2003). Oligo-
merization of adenosine A2A and dopamine D2 receptors in living
cells. Biochem. Biophys. Res. Commun. 306, 544–549.
Kataoka, M., Kawamuro, Y., Shiraki, N., Miki, R., Sakano, D., Yosh-
ida, T., Yasukawa, T., Kume, K., and Kume, S. (2013). Recovery from
diabetes in neonatal mice after a low-dose streptozotocin treat-
ment. Biochem. Biophys. Res. Commun. 430, 1103–1108.108 Stem Cell Reports j Vol. 7 j 95–109 j July 12, 2016Kikawa, K., Sakano, D., Shiraki, N., Tsuyama, T., Kume, K., Endo, F.,
and Kume, S. (2014). Beneficial effect of insulin treatment on islet
transplantation outcomes in Akita mice. PLoS One 9, e95451.
Nir, T., Melton, D.A., and Dor, Y. (2007). Recovery from diabetes in
mice by beta cell regeneration. J. Clin. Invest. 117, 2553–2561.
Persson-Sjogren, S., Forsgren, S., and Taljedal, I.B. (2002). Tyrosine
hydroxylase inmouse pancreatic islet cells, in situ and after synge-
neic transplantation to kidney. Histol. Histopathol. 17, 113–121.
Pinna, A., Bonaventura, J., Farre, D., Sanchez, M., Simola, N., Mal-
lol, J., Lluis, C., Costa, G., Baqi, Y., Muller, C.E., et al. (2014).
L-DOPA disrupts adenosine A(2A)-cannabinoid CB(1)-dopamine
D(2) receptor heteromer cross-talk in the striatum of hemiparkin-
sonian rats: biochemical and behavioral studies. Exp. Neurol.
253, 180–191.
Porat, S., Weinberg-Corem, N., Tornovsky-Babaey, S., Schyr-Ben-
Haroush, R., Hija, A., Stolovich-Rain, M., Dadon, D., Granot, Z.,
Ben-Hur, V., White, P., et al. (2011). Control of pancreatic beta
cell regeneration by glucose metabolism. Cell Metab. 13, 440–449.
Postic, C., Shiota, M., Niswender, K.D., Jetton, T.L., Chen, Y.,
Moates, J.M., Shelton, K.D., Lindner, J., Cherrington, A.D., and
Magnuson, M.A. (1999). Dual roles for glucokinase in glucose
homeostasis as determined by liver and pancreatic beta cell-spe-
cific gene knock-outs using Cre recombinase. J. Biol. Chem. 274,
305–315.
Rubi, B., Ljubicic, S., Pournourmohammadi, S., Carobbio, S., Arma-
net, M., Bartley, C., and Maechler, P. (2005). Dopamine D2-like
receptors are expressed in pancreatic beta cells andmediate inhibi-
tion of insulin secretion. J. Biol. Chem. 280, 36824–36832.
Sakano, D., Shiraki, N., Kikawa, K., Yamazoe, T., Kataoka, M.,
Umeda, K., Araki, K., Mao, D., Matsumoto, S., Nakagata, N., et al.
(2014). VMAT2 identified as a regulator of late-stage beta-cell
differentiation. Nat. Chem. Biol. 10, 141–148.
Salpeter, S.J., Klochendler, A., Weinberg-Corem, N., Porat, S.,
Granot, Z., Shapiro, A.M., Magnuson, M.A., Eden, A., Grimsby, J.,
Glaser, B., et al. (2011). Glucose regulates cyclin D2 expression in
quiescent and replicating pancreatic beta-cells through glycolysis
and calcium channels. Endocrinology 152, 2589–2598.
Sharma, A., Zangen, D.H., Reitz, P., Taneja, M., Lissauer, M.E.,
Miller, C.P., Weir, G.C., Habener, J.F., and Bonner-Weir, S.
(1999). The homeodomain protein IDX-1 increases after an early
burst of proliferation during pancreatic regeneration. Diabetes 48,
507–513.
Shuto, T., Kuroiwa,M., Hamamura,M., Yabuuchi, K., Shimazoe, T.,
Watanabe, S., Nishi, A., and Yamamoto, T. (2006). Reversal of
methamphetamine-induced behavioral sensitization by repeated
administration of a dopamine D1 receptor agonist. Neuropharma-
cology 50, 991–997.
Soderberg, O., Gullberg, M., Jarvius, M., Ridderstrale, K., Leucho-
wius, K.J., Jarvius, J., Wester, K., Hydbring, P., Bahram, F., Larsson,
L.G., et al. (2006). Direct observation of individual endogenous
protein complexes in situ by proximity ligation. Nat. Methods 3,
995–1000.
Srinivas, S., Watanabe, T., Lin, C.S., William, C.M., Tanabe, Y., Jes-
sell, T.M., and Costantini, F. (2001). Cre reporter strains produced
by targeted insertion of EYFP and ECFP into the ROSA26 locus.
BMC Dev. Biol. 1, 4.
Talchai, C., Xuan, S., Lin, H.V., Sussel, L., and Accili, D. (2012).
Pancreatic beta cell dedifferentiation as a mechanism of diabetic
beta cell failure. Cell 150, 1223–1234.
Ustione, A., and Piston, D.W. (2012). Dopamine synthesis and D3
receptor activation in pancreatic beta-cells regulates insulin secre-
tion and intracellular [Ca(2+)] oscillations. Mol. Endocrinol. 26,
1928–1940.
Ustione, A., Piston, D.W., and Harris, P.E. (2013). Minireview:
dopaminergic regulation of insulin secretion from the pancreatic
islet. Mol. Endocrinol. 27, 1198–1207.
Wu, W., Shang, J., Feng, Y., Thompson, C.M., Horwitz, S., Thomp-
son, J.R., MacIntyre, E.D., Thornberry, N.A., Chapman, K., Zhou,Y.P., et al. (2008). Identification of glucose-dependent insulin
secretion targets in pancreatic beta cells by combining defined-
mechanism compound library screening and siRNA gene
silencing. J. Biomol. Screen. 13, 128–134.
Xu, X., D’Hoker, J., Stange, G., Bonne, S., De Leu, N., Xiao, X., Van
de Casteele, M., Mellitzer, G., Ling, Z., Pipeleers, D., et al. (2008).
Beta cells can be generated from endogenous progenitors in
injured adult mouse pancreas. Cell 132, 197–207.
Yabuuchi, K., Kuroiwa, M., Shuto, T., Sotogaku, N., Snyder, G.L.,
Higashi, H., Tanaka, M., Greengard, P., and Nishi, A. (2006). Role
of adenosine A1 receptors in the modulation of dopamine D1
and adenosine A2A receptor signaling in the neostriatum. Neuro-
science 141, 19–25.Stem Cell Reports j Vol. 7 j 95–109 j July 12, 2016 109
